Stupendous opportunity to invest in Genomic Surveillance

Dr. Debjani Saha

As the nation awaits a new budget to be presented on February 1, hopes are high for the allocation towards Healthcare and Research & Development spending. The pandemic has exposed the vulnerability of our healthcare system, and continues to be fragile. Basic and translational research are the foundation for diagnostics, which in turn is the most important pillar of healthcare. We look forward to seeing investments in both.

India’s genomic surveillance has grown commendably over the past two years, and there is an increasing need to continue tracking pathogens, both new and existing ones, so that an early intervention can prevent any future crises.

Views expressed by Dr. Debjani Saha, Group Product Manager, Premas Life Sciences


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video